EMBO ReportsBiophysicsPeer-reviewed journal article
Mechanical force regulates the inhibitory function of PD-1
Hui CheniD, Yong Zhang, Lei Cui, Juan Fan, Huaying ZhuiD, Songfang WuiD, Hang ZhouiD, Yanruo Zhang, Guangtao Song, Ning Jenny JiangiD, Mingzhao ZhuiD, Changjie LouiD, Wei CheniD, Jizhong LouiD
Abstract
The immune checkpoint molecule, programmed cell death 1 (PD-1), plays a pivotal role in regulating T-cell function. Upon binding to its ligands, PD-L1 or PD-L2, PD-1 suppresses T-cell receptor signaling, thereby preventing T-cell activation, making it a critical target in cancer immunotherapy. Although extensively studied, the molecular mechanism of PD-1s inhibitory function is still not fully understood, especially at the atomic level. Using the biomembrane force probe (BFP), we discovered that interactions between PD-1 and PD-L1/PD-L2 exhibit catch-slip bond behavior under force. At lower forces, catch bonds are observed, transitioning to slip bond as the force increases. Steered molecular dynamics (SMD) simulations revealed a force-induced bond state between PD-1 and its ligands, distinct from the force-free state observed in solved complex structures. Disrupting interactions that stabilize either state weakens the catch bond and diminishes PD-1s inhibitory function. Interestingly, soluble forms of PD-L1 and PD-L2 compete with their surface-bond counterparts, attenuating PD-1s suppression of T-cell activation. This suggests that soluble PD-1 ligands could potentially serve as anti-PD-1 drugs. Tumor growth studies in mice confirmed the anti-cancer activity of soluble PD-L1. Our findings highlight the critical role of mechanical force in PD-1s inhibitory function, suggesting that PD-1 may act as a mechanical sensor in suppressing T-cell activation. These insights indicate that mechanical regulation should be considered when designing PD-1 blocking inhibitors and other PD-1 related cancer immunotherapies. TeaserThis study shows that the interaction between PD-1 and its ligands is force-dependent, and soluble forms of PD-1 ligands can potentially serve as PD-1 blockers in cancer immunotherapy.
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 1
- FWCI
- 2.94
- Field percentile
- top 13%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mechanical force regulates ligand binding and function of PD-1
K. Li, P. Cardenas-Lizana, … C. Zhu·Nature CommunicationsPeer-reviewed·Sep 27, 2024
- Deciphering PD1 activation mechanism from molecular docking and molecular dynamic simulations
Luis F. Ponce, Daniel P. Ramirez-Echemendía, … Pedro Alberto Valiente·The Journal of Physical Chemistry BPeer-reviewed·Jun 21, 2023
- PD-1 suppresses the maintenance of cell couples between cytotoxic T cells and tumor target cells within the tumor
R. Ambler, G. L. Edmunds, … C. Wuelfing·bioRxiv·Oct 16, 2018
- Myeloid DC-SIGN drives tumor immune evasion and resistance to PD-1 blockade through ICAM-2-ERM-mediated T-cell mechanosuppression
- PD-1 blockade enhances T cell activation by reorchestrating CD28 and CTLA4 ligand interactions
Gee Sung Eun, Jonathan Boyd, … Rajat Varma·bioRxiv·Apr 15, 2026
- Multiple mechanisms regulate the nanoscale organization of PD-L1 at the cell surface
Guus A. Franken, Abbey B. Arp, … Annemiek B. van Spriel·bioRxiv·Aug 31, 2026